Correspondence 0001193125-26-055328 from ENANTA PHARMACEUTICALS INC (ENTA)
ENANTA PHARMACEUTICALS INC
Date: Feb. 17, 2026 · CIK: 0001177648 · Accession: 0001193125-26-055328
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-293390
Letter
Re: Enanta Pharmaceuticals, Inc.
February 17, 2026
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form S-3
File No. 333-293390
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended (the “Act”), Enanta Pharmaceuticals, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-293390) (the “Registration Statement”), so that it may become effective at 4:00 pm Eastern time on February 20, 2026, or as soon thereafter as practicable, or at such other time as the Registrant or its outside counsel, Foley Hoag LLP, requests by telephone that such Registration Statement be declared effective. The Registrant hereby confirms that it is aware of its responsibilities under the Act.
It would be appreciated if, promptly after the Registration Statement has become effective, you would so inform our outside counsel, Stacie Aarestad of Foley Hoag LLP, by telephone at (617) 832-1108 or by email at saarestad@foleyhoag.com.
Very truly yours,
ENANTA PHARMACEUTICALS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP February 17, 2026 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Enanta Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-293390 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended (the “Act”), Enanta Pharmaceuticals, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-293390) (the “Registration Statement”), so that it may become effective at 4:00 pm Eastern time on February 20, 2026, or as soon thereafter as practicable, or at such other time as the Registrant or its outside counsel, Foley Hoag LLP, requests by telephone that such Registration Statement be declared effective. The Registrant hereby confirms that it is aware of its responsibilities under the Act. It would be appreciated if, promptly after the Registration Statement has become effective, you would so inform our outside counsel, Stacie Aarestad of Foley Hoag LLP, by telephone at (617) 832-1108 or by email at saarestad@foleyhoag.com. Very truly yours, ENANTA PHARMACEUTICALS, INC. /s/ Jay R. Luly, Ph.D. Jay R. Luly, Ph.D. President and Chief Executive Officer cc: Matthew Kowalsky, Chief Legal Officer